Title:
INHIBITORY NUCLEIC ACIDS FOR ITFG1
Document Type and Number:
WIPO Patent Application WO/2024/003148
Kind Code:
A3
Abstract:
Provided herein are nucleic acids for decreasing the expression of ITFG1, and methods for using the same, including methods of medical treatment and prophylaxis.
Inventors:
TAN YANN CHONG (SG)
TAN SI HUI (SG)
YANG BINXIA (SG)
LIN XI (SG)
TAN MEI JIA (SG)
WANG AUDREY SHIMEI (SG)
TAN SI HUI (SG)
YANG BINXIA (SG)
LIN XI (SG)
TAN MEI JIA (SG)
WANG AUDREY SHIMEI (SG)
Application Number:
PCT/EP2023/067668
Publication Date:
February 08, 2024
Filing Date:
June 28, 2023
Export Citation:
Assignee:
LERNA BIOPHARMA PTE LTD (SG)
CLEGG RICHARD IAN (GB)
CLEGG RICHARD IAN (GB)
International Classes:
C12N15/113; A61K31/7088
Domestic Patent References:
| WO2022025827A1 | 2022-02-03 |
Other References:
FAN WENJUN ET AL: "RUVBL1-ITFG1 interaction is required for collective invasion in breast cancer", BIOCHIMICA ET BIOPHYSICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 1861, no. 7, 21 March 2017 (2017-03-21), pages 1788 - 1800, XP085107810, ISSN: 0304-4165, DOI: 10.1016/J.BBAGEN.2017.03.016
IAKOVLEVA V ET AL: "OS-1290 Integrin Alpha FG-GAP Repeat Containing 1 (ITFG1) knockdown enhances liver regeneration and attenuates chronic liver damage related liver fibrosis", INTERNET CITATION, 26 June 2021 (2021-06-26), pages S233, XP009534470, ISSN: 0168-8278, Retrieved from the Internet [retrieved on 20211031]
IAKOVLEVA V ET AL: "OS-1290 Integrin Alpha FG-GAP Repeat Containing 1 (ITFG1) knockdown enhances liver regeneration and attenuates chronic liver damage related liver fibrosis", INTERNET CITATION, 26 June 2021 (2021-06-26), pages S233, XP009534470, ISSN: 0168-8278, Retrieved from the Internet
Attorney, Agent or Firm:
MEWBURN ELLIS LLP (GB)
Download PDF: